The Prescription Drug Affordability Board (PDAB) is seeking comments on its proposal to cap payment for the drug Enbrel at the Medicare price. Enbrel is one of the first Medicare Part D 10 drugs to be included in the Medicare Drug Price Negotiation Program (MDPNP) beginning January 1, 2026. Rulemaking for Enbrel began in May, and the rulemaking hearings continued on upper payment limit (UPL) for Enbrel in July and August. The fourth and possibly final rulemaking hearing on UPL for Enbrel will be on October 3.
For more information, contact NACDS’ Mary Staples at 817-442-1155.